Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"

Clinical trial NCT04920968 · RECRUITING

Trial details

NCT number: NCT04920968
Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

CD20-positive Acute Lymphoblastic Leukemia

Start date: 2021-10-05
Primary completion: 2025-12-31
Enrollment: 124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.